These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22915782)

  • 41. Association of oesophageal radiation dose volume metrics, neutropenia and acute radiation oesophagitis in patients receiving chemoradiotherapy for non-small cell lung cancer.
    Everitt S; Duffy M; Bressel M; McInnes B; Russell C; Sevitt T; Ball D
    Radiat Oncol; 2016 Feb; 11():20. PubMed ID: 26864559
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical Application of a Hybrid RapidArc Radiotherapy Technique for Locally Advanced Lung Cancer.
    Silva SR; Surucu M; Steber J; Harkenrider MM; Choi M
    Technol Cancer Res Treat; 2017 Apr; 16(2):224-230. PubMed ID: 27680023
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acute esophagitis for patients with local-regional advanced non small cell lung cancer treated with concurrent chemoradiotherapy.
    Pan Y; Brink C; Knap M; Khalil AA; Nyhus CH; McCulloch T; Holm B; Wu YL; Schytte T; Hansen O
    Radiother Oncol; 2016 Mar; 118(3):465-70. PubMed ID: 26803187
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relating acute esophagitis to radiotherapy dose using FDG-PET in concurrent chemo-radiotherapy for locally advanced non-small cell lung cancer.
    Nijkamp J; Rossi M; Lebesque J; Belderbos J; van den Heuvel M; Kwint M; Uyterlinde W; Vogel W; Sonke JJ
    Radiother Oncol; 2013 Jan; 106(1):118-23. PubMed ID: 23219463
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dosimetric rationale and early experience at UFPTI of thoracic proton therapy and chemotherapy in limited-stage small cell lung cancer.
    Colaco RJ; Huh S; Nichols RC; Morris CG; D'Agostino H; Flampouri S; Li Z; Pham DC; Bajwa AA; Hoppe BS
    Acta Oncol; 2013 Apr; 52(3):506-13. PubMed ID: 23438357
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differences in Normal Tissue Response in the Esophagus Between Proton and Photon Radiation Therapy for Non-Small Cell Lung Cancer Using In Vivo Imaging Biomarkers.
    Niedzielski JS; Yang J; Mohan R; Titt U; Mirkovic D; Stingo F; Liao Z; Gomez DR; Martel MK; Briere TM; Court LE
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):1013-1020. PubMed ID: 29063837
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Three-Arm Randomized Trial of Sodium Alginate for Preventing Radiation-Induced Esophagitis in Locally Advanced Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy: The OLCSG1401 Study Protocol.
    Ninomiya K; Ichihara E; Hotta K; Sone N; Murakami T; Harada D; Oze I; Kubo T; Tanaka H; Kuyama S; Kishino D; Bessho A; Harita S; Katsui K; Tanimoto M; Kiura K
    Clin Lung Cancer; 2017 Mar; 18(2):245-249. PubMed ID: 27847247
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Endoscopic findings of radiation esophagitis in concurrent chemoradiotherapy for intrathoracic malignancies.
    Hirota S; Tsujino K; Hishikawa Y; Watanabe H; Kono K; Soejima T; Obayashi K; Takada Y; Kono M; Abe M
    Radiother Oncol; 2001 Mar; 58(3):273-8. PubMed ID: 11230888
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oral glutamine supplements reduce concurrent chemoradiotherapy-induced esophagitis in patients with advanced non-small cell lung cancer.
    Chang SC; Lai YC; Hung JC; Chang CY
    Medicine (Baltimore); 2019 Feb; 98(8):e14463. PubMed ID: 30813149
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial.
    Rosenman JG; Halle JS; Socinski MA; Deschesne K; Moore DT; Johnson H; Fraser R; Morris DE
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):348-56. PubMed ID: 12243807
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic factors, patterns of recurrence and toxicity for patients with esophageal cancer undergoing definitive radiotherapy or chemo-radiotherapy.
    Haefner MF; Lang K; Krug D; Koerber SA; Uhlmann L; Kieser M; Debus J; Sterzing F
    J Radiat Res; 2015 Jul; 56(4):742-9. PubMed ID: 25907360
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lower Incidence of Esophagitis in the Elderly Undergoing Definitive Radiation Therapy for Lung Cancer.
    Soni PD; Boonstra PS; Schipper MJ; Bazzi L; Dess RT; Matuszak MM; Kong FM; Hayman JA; Ten Haken RK; Lawrence TS; Kalemkerian GP; Jolly S
    J Thorac Oncol; 2017 Mar; 12(3):539-546. PubMed ID: 28161553
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predicting Radiation Esophagitis Using 18F-FDG PET During Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer.
    Mehmood Q; Sun A; Becker N; Higgins J; Marshall A; Le LW; Vines DC; McCloskey P; Ford V; Clarke K; Yap M; Bezjak A; Bissonnette JP
    J Thorac Oncol; 2016 Feb; 11(2):213-21. PubMed ID: 26718880
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase I study of concurrent high-dose three-dimensional conformal radiotherapy with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small-cell lung cancer.
    Sekine I; Sumi M; Ito Y; Horinouchi H; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Kubota K; Tamura T
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):953-9. PubMed ID: 21377282
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
    Uyterlinde W; Belderbos J; Baas C; van Werkhoven E; Knegjens J; Baas P; Smit A; Rikers C; van den Heuvel M
    Clin Lung Cancer; 2013 Sep; 14(5):541-8. PubMed ID: 23835165
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predictors of high-grade esophagitis after definitive three-dimensional conformal therapy, intensity-modulated radiation therapy, or proton beam therapy for non-small cell lung cancer.
    Gomez DR; Tucker SL; Martel MK; Mohan R; Balter PA; Lopez Guerra JL; Liu H; Komaki R; Cox JD; Liao Z
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):1010-6. PubMed ID: 22920974
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Factors associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer.
    Watkins JM; Wahlquist AE; Shirai K; Garrett-Mayer E; Aguero EG; Fortney JA; Sherman CA; Sharma AK
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1108-13. PubMed ID: 19084345
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of brain stem and dorsal vagus complex dosimetry on nausea and vomiting in head and neck intensity-modulated radiation therapy.
    Ciura K; McBurney M; Nguyen B; Pham M; Rebueno N; Fuller CD; Guha-Thakurta N; Rosenthal DI
    Med Dosim; 2011; 36(1):41-5. PubMed ID: 20097059
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery.
    Wang SL; Liao Z; Vaporciyan AA; Tucker SL; Liu H; Wei X; Swisher S; Ajani JA; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):692-9. PubMed ID: 16242257
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Subjective Global Assessment (SGA) Score Could Be a Predictive Factor for Radiation Pneumonitis in Lung Cancer Patients With Normal Pulmonary Function Treated by Intensity-Modulated Radiation Therapy and Concurrent Chemotherapy.
    Ma L; Ye W; Li Q; Wang B; Luo G; Chen Z; Guo S; Qiu B; Liu H
    Clin Lung Cancer; 2018 Mar; 19(2):e211-e217. PubMed ID: 29017827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.